Online inquiry

IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2632MR)

This product GTTS-WQ2632MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets IL2RB gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001290023.2; NM_001258214.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3594; 3595
UniProt ID P42701; Q99665
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2632MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13081MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ5749MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ8443MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HspE7
GTTS-WQ7186MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ2011MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ13383MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ6088MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ12657MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-131R10
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW